News and Features
Call for Nominations for New Scientific/Clinical Members for the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents
The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) is accepting nominations for new scientific/clinical members with expertise in HIV medicine. The Panel is seeking candidates with expertise in HIV clinical care and research who can critically evaluate new information and help prepare guideline revisions. Candidates for Panel membership shall be recognized experts in their areas of interest, with outstanding records of publication and presentation. Individuals from diverse backgrounds, those from underrepresented geographic areas, and women are strongly encouraged to apply.
Successful candidates will serve a 4-year term beginning March 2012, with potential for reappointment for a second term. Panel members are not compensated for their time commitment and travel support is generally not provided.
The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of approximately 35 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. Panel members meet monthly via teleconference and annually in person to review and critically evaluate emerging scientific data relating to antiretroviral therapy and to revise the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. (To review the latest revision of the guidelines, which was published on January 10, 2011, visit the AIDSinfo Clinical Guidelines Portal.)
Please include with nominations the candidate’s curriculum vitae and a letter detailing how the nominee’s expertise would contribute to the work of the Panel. Self-nominations are welcome.
The deadline for nominations is October 14, 2011, and submissions can be e-mailed to Alice Pau, Pharm.D. at firstname.lastname@example.org or sent to the address below.
Alice K. Pau, Pharm.D., FIDSA
Executive Secretary, HHS Panel on Antiretroviral Guidelines for Adults and Adolescents
NIAID-NIH, Building 10, Room 11C103, MSC 1880
Bethesda, MD 20892
NIAID Researchers Discuss Challenges to Developing Broadly Protective HIV Vaccines
“The human body can produce powerful antibodies that shield cells in the laboratory against infection by an array of HIV strains. In people, however, recent research shows that these broadly neutralizing antibodies are not produced in an efficient or timely enough fashion in HIV-infected individuals to effectively block progression of infection, appearing only after a person has been infected with HIV for at least one year—by which time the virus has fully established itself within the body. In a Perspective article appearing this week in the New England Journal of Medicine, scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, assert that a key research goal is to develop HIV vaccines that prevent HIV infection by inducing more effective immune responses than those that occur naturally.
“In their article, the authors examine the challenges of developing HIV vaccines that can effectively induce these broadly neutralizing antibodies. Specifically, they describe work under way to design structure-based HIV vaccines, as well as efforts to gain a better understanding of the evolutionary processes that human B cells undergo to produce broadly neutralizing HIV antibodies. The authors conclude that the availability of new research tools, together with the increased understanding of the human immune response to HIV, make them optimistic that an HIV vaccine that provides significant protection against acquisition of HIV infection can be achieved.”
More information is available:
- NIAID: Press release
- AIDSinfo: Clinical Trials Search Page - HIV Preventive Vaccines
Fall 2011 Issue of mental health AIDS Now Available
The quarterly biopsychosocial research update on HIV and mental health, mental health AIDS, is sponsored by the Center for Mental Health Services (CMHS) of the Substance Abuse and Mental Health Services Administration (SAMHSA) and is disseminated free of charge through the SAMHSA Web site.
The Fall 2011 issue features an article titled, “Positively Golden: Advances in Aging with HIV (Part 2).”
Part 1 of this series highlighted recent research findings on medical and neurocognitive concerns associated with HIV and aging. A characterization of “successful cognitive aging” with HIV was presented, as were performance-based measures to identify functional impairment attributable to aging and HIV and cognitive remediation strategies for use with people who exhibit cognitive decline while aging with HIV.
This concluding segment first describes a “positive aging” framework not specific to HIV infection; a strengths-based model of coping, along with three meaning-centered strategies grounded within this model: gratitude, forgiveness, and altruism; and then the infusion of “positive aging” concepts into qualitative and quantitative research on adults aging with HIV infection. The article also discusses the first controlled clinical trial to assess if an age-appropriate, coping improvement group intervention could benefit older adults living with HIV/AIDS who have depressive symptoms.
More information is available: